HAPPYMINI® IN THE HALLUX RIGIDUS The ISIAT 2019 held in Lisbon in October was the occasion for LABRHA to present a study about HAppyMini® in the Hallux Rigidus (Osteoarthritis of the first metatarso-phalangeal joint). This prospective open-label multicentre pilot trial was conducted on 65 patients and safety was very good Read more…
New Publication about Cuivramine® with the PREDOA Study conducted on more than 2000 patients Guidelines recommend symptomatic slow-acting drugs for OA (SYSADOA) to reduce pain and avoid the use of NSAIDs. However, the main issue with slow-acting treatments is the poor adherence. In this study, we could observe an excellent compliance, higher than expected with Read more…
This prospective pilot study was conducted to show the Safety & Efficacy of a Single Injection of Mannitol-modified Cross-Linked Hyaluronic Acid (HAppyMini®) in the treatment of the Temporo-Mandibular Osteoartritis. Results at D180 : Treatment was efficient or very efficient for 94% of the patients Long lasting improvment of the inter-incisal distance 2/3 of patients reduced their painkillers Read more…
Like every year since 2012, LABRHA attended the EULAR Annual Meeting which took place in Amsterdam from the 13th to the 16th of June 2018. During the scientific session on “OSTEOARTHRITIS and microcrystalline disease”, Dr Thierry CONROZIER (France) presented results of the INSTINCT Study: influence of the radiological grade on the efficacy Read more…
LABRHA took part in the 30th annual Congress of the French Society of Rheumatology (SFR) which took place last 10th to 12th of December in Paris. During this congress LABRHA presented its latest scientific works in 2 oral communication presentations and 2 posters. ORAL COMMUNICATIONS 1 // Influence of the Read more…